Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




New NGS Solutions Provide Powerful Tool for Myeloid Research with Highly Efficient Workflow

By LabMedica International staff writers
Posted on 06 Oct 2022

OGT (Oxford, UK), a Sysmex Group (Kobe, Japan) company, has launched several new solutions to support its growing next-generation sequencing (NGS) portfolio. More...

These include the SureSeq Myeloid Plus panel, which has been designed to detect aberrations in genes implicated in a variety of Myeloid disorders. Additionally, OGT has also launched a new improved library preparation workflow - the OGT Universal NGS Complete Workflow, compatible with its hematology, inherited and rare disease NGS panels - significantly reducing hands-on time and complemented by updated Interpret NGS Analysis software.

The SureSeq Myeloid Plus panel is the most recent addition to OGT’s hematology NGS portfolio. Having been meticulously designed along-side leading cancer experts, the new panel is able to detect a comprehensive range of aberrations including SNVs, indels, ITDs and PTDs within 49 genes. These genes cover those associated with myeloid disorders including acute myeloid leukemia, myeloproliferative neoplasms and myelodysplastic syndrome among others. Thanks to OGT’s vast expertise in bait design, the Myeloid Plus panel delivers unparalleled coverage uniformity for low frequency variants, even in difficult-to-sequence AT/GC rich regions and challenging regions covering ITDs and PTDs, which are common somatic variants in acute myeloid leukemia (AML) often associated with poor prognosis and an aggressive form of the disease. The power of the Myeloid Plus panel stands testament to the benefits of hybridization capture over PCR enrichment for unrivalled levels of sensitivity and uniformity of coverage.

To support researchers using the SureSeq Myeloid Plus panel, and all of OGT’s SureSeq hematology and CytoSure NGS panels, the new Universal NGS Complete Workflow has been developed. By reducing the number of clean-up steps and QC requirements, library preparation can be completed in just four and a half hours, with a 40% saving of hands-on time. By combining several steps, and introducing sample pooling, the reduced workflow complexity not only decreases the potential for error, but also saves on plastic waste and costs.

Compared to the previous SureSeq workflow, the updated version requires no additional expensive laboratory equipment, making the process much more amenable to automation, and therefore ready for the future. To supplement this new and improved workflow, OGT’s renowned Interpret NGS Analysis software (V3.5) has been upgraded with improvements in CNV interpretation, annotation, visualization and sample data import and display. Unlike many other NGS providers, OGT provides complimentary NGS software with its NGS panels, demonstrating the company’s commitment to sharing technology, and technical expertise to support NGS research around the globe.

“At OGT, we are experts in delivering high efficiency NGS workflows with best-in-class gene panels, software, and library preparation solutions,” said Adrian Smith, Chief Executive Officer of OGT. “Thanks to our unmatched expertise in bait design, and through partnering with leading cancer experts, we have developed a powerful tool for myeloid research with a highly efficient workflow. This enables clinical researchers to quickly and confidently detect all relevant variants in one simple assay. NGS is a key area of expertise for OGT, and we have exciting plans and possibilities for the future.”

Related Links:
OGT
Sysmex Group


New
Gold Member
Serological Pipets
INTEGRA Serological Pipets
POC Helicobacter Pylori Test Kit
Hepy Urease Test
New
8-Channel Pipette
SAPPHIRE 20–300 µL
New
Autoimmune Disease Diagnostic
Chorus ds-DNA-G
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Molecular Diagnostics

view channel
Image: Illustration of a cross-section of a blood vessel with red blood cells, white blood cells, and fragments of DNA (Photo Courtesy of UC San Diego/Adobe Firefly)

Microbial DNA Signature in Blood Plasma Differentiates Two Liver Cancer Types

Determining whether a cancerous tumor originated in a given location or spread from another organ is critical for guiding diagnosis and treatment decisions. When the primary tumor site cannot be identified,... Read more

Immunology

view channel
Image: The test could streamline clinical decision-making by identifying ideal candidates for immunotherapy upfront (Xiao, Y. et al. Cancer Biology & Medicine July 2025, 20250038)

Blood Test Predicts Immunotherapy Efficacy in Triple-Negative Breast Cancer

Triple-negative breast cancer (TNBC) is an aggressive subtype lacking targeted therapies, making immunotherapy a promising yet unpredictable option. Current biomarkers such as PD-L1 expression or tumor... Read more

Microbiology

view channel
Image: New diagnostics could predict a woman’s risk of a common sexually transmitted infection (Photo courtesy of 123RF)

New Markers Could Predict Risk of Severe Chlamydia Infection

Chlamydia trachomatis is a common sexually transmitted infection that can cause pelvic inflammatory disease, infertility, and other reproductive complications when it spreads to the upper genital tract.... Read more

Pathology

view channel
Image: (A) Normal skin and (B) possible pathology in ALS skin (Photo courtesy of Biomolecules and Biomedicine (2025) DOI: 10.17305/bb.2025.12100)

Skin-Based Biomarkers to Enable Early Diagnosis of Amyotrophic Lateral Sclerosis

Amyotrophic lateral sclerosis (ALS) is a progressive neurodegenerative disease that damages motor neurons in the brain and spinal cord, causing muscle weakness, paralysis, and death within three to five... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.